Wedbush Keeps Their Buy Rating on Zafgen (ZFGN)

By Austin Angelo

Wedbush analyst Liana Moussatos reiterated a Buy rating on Zafgen (ZFGNResearch Report) yesterday and set a price target of $6. The company’s shares closed yesterday at $2.61, close to its 52-week low of $2.33.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -6.1% and a 38.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Zafgen has an analyst consensus of Strong Buy, with a price target consensus of $7.

See today’s analyst top recommended stocks >>

The company has a one-year high of $12.36 and a one-year low of $2.33. Currently, Zafgen has an average volume of 284.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases.